Newsfeeds - Spark Newswire

1 minute read

Penumbra Q2 Adj. EPS $0.21 Beats $0.17 Estimate, Sales $184.26M Beat $170.76M Estimate

Today, 2:38 PM

Penumbra (NYSE:PEN) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.17 by 23.53 percent. This is a 170 percent increase over losses of $(0.30) per share from the same period

PEN

14 minute read

Earnings Scheduled For August 9, 2021

By Benzinga Insights

Today, 2:38 PM

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.

ACM

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

Today, 2:38 PM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 4, 2021

By Benzinga Insights

Today, 2:38 PM

ADS

1 minute read

BTIG Upgrades Penumbra to Buy, Announces $291 Price Target

By Benzinga Newsdesk

Today, 2:38 PM

BTIG analyst Ryan Zimmerman upgrades Penumbra (NYSE:PEN) from Neutral to Buy and announces $291 price target.

PEN

20 minute read

Uncategorized

Earnings Scheduled For May 4, 2021

By Benzinga Insights

Today, 2:38 PM

Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million.

ACLS

8 minute read

Uncategorized

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge

By Shanthi Rexaline

Today, 2:38 PM

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.

ABUS